Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study (Q56384328)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

Lorenza Rimassa

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Vittorina Zagonel

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Vincenzo Mazzaferro

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Carlos Lopez Lopez

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Nicola Personeni

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Armando Santoro

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Eric Assenat

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Markus Peck-Radosavljevic

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Marc Pracht

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Philippe Mathurin

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Elena Rota Caremoli

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Camillo Porta

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Bruno Daniele

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Luigi Bolondi

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

William Harris

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Nevena Damjanov

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Davide Pastorelli

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Jennifer Knox

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Francesca Negri

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Jörg Trojan

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Marie Dupuy

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Wolfgang Sieghart

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Giovanni Abbadessa

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Maria Lamar

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Terri Goldberg

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Dale Shuster

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

language of work or name

0 references

publication date

3 April 2018

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

682-693

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the HGF/Met signaling pathway in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tivantinib (ARQ197) in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930146-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30146-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29625879%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56384328&oldid=2030960598"